Get the Stockscreener App
5.33
0.95%
0.05
After Hours:
5.36
0.03
+0.56%
Verastem Inc stock is traded at $5.33, with a volume of 694.70K.
It is up +0.95% in the last 24 hours and up +15.87% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$5.28
Open:
$5.31
24h Volume:
694.70K
Relative Volume:
0.46
Market Cap:
$237.22M
Revenue:
$3.64M
Net Income/Loss:
$-87.37M
P/E Ratio:
-1.2968
EPS:
-4.11
Net Cash Flow:
$-86.46M
1W Performance:
-6.98%
1M Performance:
+15.87%
6M Performance:
+55.85%
1Y Performance:
-52.03%
1-Day Range:
$5.12
$5.42
1-Week Range:
$5.01
$6.02
52-Week Range:
$2.10
$14.22
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.33 | 237.22M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
Verastem Stock Soars 46% After FDA Grants Priority Review for Cancer Treatment – Market - HPBL
Verastem stock retains Buy rating as KRASG12D program and LGSOC launch gain traction - Investing.com Canada
Verastem, Inc. (NASDAQ:VSTM) Shares Sold by Jane Street Group LLC - Defense World
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - BioSpace
Verastem Oncology Names Pharma Veteran Matthew Ros as COO Ahead of Key Cancer Drug Launch - StockTitan
Verastem Oncology Appoints Matthew E. Ros as Chief Operating Officer - Marketscreener.com
Dan Paterson Sells 8,568 Shares of Verastem, Inc. (NASDAQ:VSTM) Stock - MarketBeat
Verastem CEO sells shares worth $44,896 By Investing.com - Investing.com Australia
Verastem CEO sells shares worth $44,896 - Investing.com India
Verastem licenses GenFleet's KRAS inhibitor - The Pharma Letter
Verastem Licenses Investigational Cancer Drug VS-7375 from GenFleet, Shares Rise 4.1% – Market - HPBL
Verastem Oncology: $150 Million Credit Facility Deal Signed - Pulse 2.0
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China - Business Wire
Verastem Oncology announces debt refinancing with Oberland Capital - MSN
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 - BioSpace
Verastem Oncology Secures $150M Credit Facility, IQVIA Partnership for Cancer Drug Launch - StockTitan
Royal Bank of Canada Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) Stock - Defense World
FDA reviewing oral combination treatment for ovarian cancer - Myeloma Research News
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
Follicular Lymphoma Market Expected to rise, 2034 | - openPR
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Verastem's SWOT analysis: biotech firm's stock rides on avutometinib approval - Investing.com India
Barclays PLC Has $167,000 Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Geode Capital Management LLC Raises Stock Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem Oncology Grants Stock Options to New Employee at $6.49 Exercise Price - StockTitan
Chugai Pharmaceutical Co., Ltd.Verastem Oncology's Announcement Regarding Avutometinib - Marketscreener.com
Royal Bank of Canada Issues Positive Forecast for Verastem (NASDAQ:VSTM) Stock Price - MarketBeat
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag - MSN
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of “Buy” from Analysts - Defense World
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Verastem: Planning The PDUFA Run-Up (NASDAQ:VSTM) - Seeking Alpha
State Street Corp Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem: BLA Acceptance Puts Key Goals In Sight (NASDAQ:VSTM) - Seeking Alpha
Verastem soars on FDA priority review for avutometinib - The Pharma Letter
Verastem stock climbs on raised price target and FDA milestone for KRASm treatment - Investing.com Nigeria
Verastem stock remains volatile but promising data reinforces Buy rating by B.Riley - Investing.com Canada
BTIG Research Issues Positive Forecast for Verastem (NASDAQ:VSTM) Stock Price - Defense World
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Thera - GuruFocus.com
Verastem Shares Soar on FDA Priority Review of Cancer Treatment - Marketscreener.com
FDA sets priority review date for Verastem’s new ovarian cancer drug - The Business Journals
Regulatory Milestone Sends Verastem (VSTM) Shares Soaring - Stocks Telegraph
Stifel Financial Corp Buys 11,642 Shares of Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application - Yahoo Finance
Verastem (NASDAQ:VSTM) Price Target Raised to $20.00 at BTIG Research - MarketBeat
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - BioSpace
Verastem Oncology's New Cancer Treatment Gets FDA Priority Review - Marketscreener.com
FDA accepts Verastem NDA for priority review, stock jumps 20% (update) - Seeking Alpha
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):